ATE549350T1 - Neuropeptid-2-rezeptor-agonisten - Google Patents

Neuropeptid-2-rezeptor-agonisten

Info

Publication number
ATE549350T1
ATE549350T1 AT06830133T AT06830133T ATE549350T1 AT E549350 T1 ATE549350 T1 AT E549350T1 AT 06830133 T AT06830133 T AT 06830133T AT 06830133 T AT06830133 T AT 06830133T AT E549350 T1 ATE549350 T1 AT E549350T1
Authority
AT
Austria
Prior art keywords
neuropeptide
receptor agonists
agonists
receptor
Prior art date
Application number
AT06830133T
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
George Ehrlich
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Rebecca Anne Taub
Jefferson W Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE549350T1 publication Critical patent/ATE549350T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06830133T 2005-12-07 2006-11-27 Neuropeptid-2-rezeptor-agonisten ATE549350T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30
PCT/EP2006/068924 WO2007065808A2 (en) 2005-12-07 2006-11-27 Neuropeptide-2 receptor-agonists

Publications (1)

Publication Number Publication Date
ATE549350T1 true ATE549350T1 (de) 2012-03-15

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830133T ATE549350T1 (de) 2005-12-07 2006-11-27 Neuropeptid-2-rezeptor-agonisten

Country Status (18)

Country Link
US (2) US7642244B2 (de)
EP (1) EP1962959B1 (de)
JP (1) JP5000663B2 (de)
KR (1) KR101059602B1 (de)
AR (1) AR057222A1 (de)
AT (1) ATE549350T1 (de)
AU (1) AU2006324076A1 (de)
BR (1) BRPI0619573A2 (de)
CA (1) CA2630649A1 (de)
EC (1) ECSP088511A (de)
ES (1) ES2381497T3 (de)
IL (1) IL191636A (de)
MA (1) MA30142B1 (de)
NO (1) NO20082445L (de)
NZ (1) NZ568772A (de)
RU (2) RU2430108C2 (de)
TW (1) TWI321474B (de)
WO (1) WO2007065808A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
WO2007065808A2 (en) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CA2741921A1 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
EP2477643A1 (de) * 2009-09-18 2012-07-25 Novo Nordisk A/S V2-rezeptoragonisten mit langzeitwirkung
CA2776302A1 (en) * 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
CN103282054A (zh) 2011-01-03 2013-09-04 弗·哈夫曼-拉罗切有限公司 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
EP2827885B1 (de) 2012-03-22 2018-08-15 Novo Nordisk A/S Zusammensetzungen von glp-1-peptiden und ihre herstellung
SI2869848T1 (sl) 2012-07-04 2017-01-31 F. Hoffmann-La Roche Ag Kovalentno vezani konjugati antigen-protitelo
CA2872184A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
RU2630296C2 (ru) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Антитела к биотину и способы их применения
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (de) 2013-11-15 2019-03-06 Novo Nordisk A/S Beta-homoarginin substitution an position 35 von hpyy(1-36)
MX373017B (es) 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
MX373856B (es) 2014-01-03 2020-03-25 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016275735B2 (en) 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP4299118A3 (de) 2018-02-02 2024-04-10 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
EP0692971A4 (de) * 1993-03-29 1997-11-12 Univ Cincinnati Peptid yy-analogen und verwendungen dafür
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
MXPA02000927A (es) * 1999-07-28 2003-07-14 Johnson & Johnson Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos.
EP1583549A4 (de) * 2003-01-17 2006-10-04 Sod Conseils Rech Applic Yy-peptid-analoga
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US20090105122A1 (en) 2003-11-25 2009-04-23 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP1718671A2 (de) 2004-02-23 2006-11-08 Rheoscience A/S Peptid-yy-analoga
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
WO2007065808A2 (en) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
EP1962959A2 (de) 2008-09-03
CA2630649A1 (en) 2007-06-14
IL191636A0 (en) 2008-12-29
US8268784B2 (en) 2012-09-18
KR20080082672A (ko) 2008-09-11
WO2007065808A2 (en) 2007-06-14
JP5000663B2 (ja) 2012-08-15
TWI321474B (en) 2010-03-11
NZ568772A (en) 2010-05-28
ES2381497T3 (es) 2012-05-28
RU2430108C2 (ru) 2011-09-27
WO2007065808A3 (en) 2007-08-02
MA30142B1 (fr) 2009-01-02
KR101059602B1 (ko) 2011-08-25
AU2006324076A1 (en) 2007-06-14
EP1962959B1 (de) 2012-03-14
US20070135351A1 (en) 2007-06-14
ECSP088511A (es) 2008-07-30
RU2008127265A (ru) 2010-01-20
JP2009518349A (ja) 2009-05-07
NO20082445L (no) 2008-09-03
US7642244B2 (en) 2010-01-05
BRPI0619573A2 (pt) 2011-10-04
AR057222A1 (es) 2007-11-21
US20100137223A1 (en) 2010-06-03
IL191636A (en) 2012-10-31
TW200806311A (en) 2008-02-01
RU2011105310A (ru) 2012-08-20

Similar Documents

Publication Publication Date Title
DE602006007563D1 (de) Agonisten
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
EP1931352A4 (de) Tlr-agonisten
DK1928882T3 (da) (s)-n-methylnaltrexon
DK3354273T3 (da) Melanocortinreceptorligander
ATE408603T1 (de) Pyrazolylcarboxanilide
EP1981902A4 (de) Nogo-rezeptorantagonisten
CR9974A (es) Gavión
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE602006020447D1 (de) Niacin-rezeptoragonisten, zusammensetzungen mit de
ATE549324T1 (de) Tetrahydrobenzoxazine
DK1870409T3 (da) Benzimidazolforbindelser
ES1064680Y (es) Estructura portante de receptor
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE102005052834B8 (de) Punktschweißklebverbindung
DE602006021285D1 (de) Mikrotomklinge
ATE485368T1 (de) Hiv - impfung
AT501523A3 (de) Estrich
DK1904404T3 (da) Mærkede uorganiske additiver
DE502006000445D1 (de) Mulchmähdeck
DE102006033170A8 (de) Einfassnähmaschine
DE502006002822D1 (de) Ges